Hi RMB It appears to me based on the filings I've read / scanned ...that HSCS now has more cash on hand then CDIO. Both have major challenges . CDIO's blood test is still $350 a pop and unlikely to be covered by insurance . This is my understanding anyway based on the view of Dew ( biotech values ) re insurance coverage for new diagnostics . I don't have a position in CDIO as I think its a huge momo play . HSCS was on deaths door about to be delisted and have just announced via an 8K receiving $6m which apparently brings them in to SEC compliance ...at least for now. HSCS 's technology was developed at the Icahn School of Medicine and the inventors hold positions in the stock. Much rests on FDA guidance re path to approval . Both are hugely speculative . I'm surprised at how far and how fast CDIO has run given the limited amount of cash on hand they seem to have and IMHO limited chances of their blood test ever being covered by insurance . Huge vol in HSCS today Happy Thanksgiving Kiwi
RMB. based on the 8K filings after the close .....this looks like a classic ( sorry to say and I may well be wrong ) ...a classic pump and dump. The pump is their " breakthrough " diagnostic blood test being published ....and now looking at the proxy card ... they want to issue a lot more shares . They need the cash ...so issuing shares will get them the cash ...but dilute existing shareholders . Of course this notice comes out after the close , right before Thanksgiving ...classic No position Kiwi
News 
Market Data 
Discover 
